A further point to consider is that SRX is due to report its...

A further point to consider is that SRX is due to report its results from HCC prior to BTG phase III trials which have been relatively slow to enroll patients. IF SRX reports successful results for HCC, then it will be hard for oncologists to recommend Theraspheres. Moreover, BTG has a very limited indication for its theraspheres ... again IF SRX reports good results from HCC trials it can petition FDA to revoke BTG indication. In any event there is room in the market for both - subject to the trials being successful.

Re: OSL and possible Liver treatments .... Clinical trials are so far away, that its not likely to be a threat to either SRX or BTG.